CTE Shares Cryosite Limited
ASX · ASXLast in our picks 2026-10-15 — not in the current list; analysis below is from that screen
Healthcare infrastructure and biostorage exposure provides steadier fundamentals than development-stage biotechnology names.
Future value: $1.50 (+24.48%) · 6-12 months
Signal breakdown
- ▸Positive momentum and operating profitability.
- ▾Below 50-day MA (-0.18%)
- ▸Above 200-day MA — long-term uptrend
- ▸~24% upside to price target
Is CTE a buy right now?
Trend: CTE is trading above the 50-day average (+0.83%), RSI 42 — neutral momentum, with a 3-month return of +1.67%.
Valuation & quality: Cryosite Limited trades on a trailing P/E of 30.5, PEG 1.53, price-to-book 12.32; fundamentals show net margin 13.4%, return on equity 61.7%, revenue growth 12.7% year on year.
Our screen: BUY (score 3) — Healthcare infrastructure and biostorage exposure provides steadier fundamentals than development-stage biotechnology names.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.10% | +4.50% | -4.30% | +13.60% | -4.00% | +4.20% | -8.00% | +6.10% |
Fundamentals
Technical signals
About Cryosite Limited
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments.
Sector: Healthcare · Industry: Diagnostics & Research · Australia · 27 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.